The Third Circuit Court of Appeals recently ruled on a significant class action lawsuit involving GlaxoSmithKline LLC (GSK) and its diabetes medication, Avandia. The court addressed whether third-party payors (TPPs) could proceed with their claims against GSK for allegedly misrepresenting the drug's cardiovascular risks. This ruling affects numerous health plans and may set important precedents for similar pharmaceutical cases.
The case, officially titled In re: Avandia Marketing, Sales Practices and Products Liability Litigation, was filed under docket number 25-2278. It centers on claims that GSK misled healthcare providers about Avandia's safety, leading to increased prescriptions and, consequently, higher costs for TPPs that reimbursed these prescriptions. The court's decision has implications for how pharmaceutical companies market their products and how courts evaluate class action certifications.
Background
In 1999, the Food and Drug Administration (FDA) approved Avandia as a treatment for Type II diabetes, marketed by GSK as a drug that could not only manage blood sugar but also reduce cardiovascular risks. Despite its higher cost compared to older alternatives like metformin, Avandia quickly became popular among healthcare providers, resulting in substantial sales for GSK.
However, internal studies conducted by GSK began to reveal concerning findings about Avandia's cardiovascular risks. Despite these findings, GSK did not immediately update the drug's labeling or inform the FDA. Public awareness of the risks surged after a 2007 study published in the New England Journal of Medicine highlighted the drug's association with increased heart attack risks. Following this revelation, the FDA mandated a black-box warning on Avandia, leading to a significant drop in prescriptions.
In 2010, several TPPs, including the United Food and Commercial Workers Local 1776 and Participating Employers Health and Welfare Fund, filed a class action lawsuit against GSK, alleging violations of the Racketeer Influenced and Corrupt Organizations Act (RICO) and various state laws. They claimed GSK's fraudulent marketing practices caused them to incur unnecessary costs by covering Avandia prescriptions that they would not have otherwise approved.
The Ruling
The Third Circuit Court of Appeals ultimately ruled that the proposed class of TPPs was ascertainable, meaning that the court found a reliable method for identifying class members. However, the court disagreed with the lower court's conclusion that common issues predominated regarding causation. The judges emphasized that the plaintiffs must demonstrate a causal link between GSK's misrepresentations and the increased prescriptions of Avandia.
The court stated, "We do not presume in law that x caused y merely because x happened first. The connection might be causal. But it might be coincidental. Or some z might be responsible for x and y alike."
Judge Ambro, along with Judges Schwartz and Montgomery-Reeves, highlighted the need for statistical evidence to establish causation rather than mere correlation. The court vacated the lower court's class certification ruling and remanded the case for further fact-finding on the predominance of common issues.
Impact
This ruling has far-reaching implications for pharmaceutical companies and TPPs. It underscores the importance of establishing a clear causal link when alleging fraudulent marketing practices. The court's requirement for robust statistical evidence to demonstrate causation may set a higher standard for future class action lawsuits against pharmaceutical companies.
For TPPs, this decision means they must prepare to present stronger evidence in support of their claims if they wish to pursue class action lawsuits against drug manufacturers. The ruling may also encourage more rigorous scrutiny of drug marketing practices and the evidence required to support claims of misrepresentation.
What's Next
The case has been sent back to the lower court for further proceedings, where the TPPs will need to gather additional evidence to meet the clarified standard for causation. It remains to be seen whether GSK will appeal this decision or if there are related cases pending that could further influence the outcome of this litigation.